Backed by Hen­ri Ter­meer es­tate, Au­ra rais­es $30M for work to pre­vent blind­ness in eye can­cer pa­tients

Cam­bridge, MA biotech Au­ra Bio­sciences has raised $30 mil­lion in a Se­ries C round to take its light-ac­ti­vat­ed nanopar­ti­cle tech in­to late-stage tri­als for eye can­cer.

Elis­a­bet de los Pinos

With the new cash, Au­ra plans to fi­nance its Phase Ib/II tri­al of the com­pa­ny’s lead ther­a­py AU-011. The prod­uct can­di­date is be­ing test­ed in pa­tients with a rare eye can­cer called oc­u­lar melanoma. Even though the can­cer is of­ten caught in its ear­ly stages, pa­tients of­ten go blind due to how the can­cer is cur­rent­ly treat­ed. Au­ra’s founder and CEO Elis­a­bet de los Pinos tells me this eye can­cer is cur­rent­ly treat­ed with ra­dioac­tiv­i­ty since surgery is not pos­si­ble.

“Ra­dioac­tiv­i­ty is the on­ly tool they have. And when you ad­min­is­ter ra­dioac­tiv­i­ty in the eye, blind­ness is the col­lat­er­al dam­age,” de los Pinos said.

Au­ra’s in­ves­ti­ga­tion­al ther­a­py may pre­vent that. The ther­a­py con­sists of vi­ral nanopar­ti­cles that bind with can­cer cells in the eye. The com­pa­ny says the nanopar­ti­cles, mod­eled on the hu­man pa­pil­lo­mavirus, are “light-ac­ti­vat­ed.” This means up­on ac­ti­va­tion with an oph­thalmic laser, the small mol­e­cules se­lec­tive­ly de­stroy the mem­brane of can­cer cells, killing them with­out dam­ag­ing the over­lay­ing reti­na. This might en­able pa­tients to re­tain vi­sion de­spite fight­ing this rare and life-threat­en­ing form of eye can­cer. The FDA grant­ed the com­pa­ny or­phan drug des­ig­na­tion for the ther­a­py.

Au­ra has al­ready re­leased pos­i­tive in­ter­im da­ta from its on­go­ing Phase Ib/II study, and will con­tin­ue en­rolling pa­tients with ear­ly-stage oc­u­lar melanoma.

Mark Chin

The com­pa­ny’s new in­fu­sion of cash was led by new in­vestors Lund­beck­fonden Ven­tures and Ar­ix Bio­science, with all cur­rent in­vestors — in­clud­ing the es­tate of Hen­ri Ter­meer — al­so par­tic­i­pat­ing. The round brings the com­pa­ny’s to­tal raise to $79 mil­lion since its in­cep­tion in 2009.

“We be­lieve that this time­ly in­vest­ment will pro­pel the com­pa­ny’s prepa­ra­tions for late-stage stud­ies of AU-011 and ad­di­tion­al ap­pli­ca­tions of its pro­pri­etary vi­ral nanopar­ti­cle con­ju­gate tech­nol­o­gy,” said Mark Chin, in­vest­ment man­ag­er at Ar­ix Bio­science, in a state­ment.

De los Pinos said those ad­di­tion­al ap­pli­ca­tions in­clude us­ing Au­ra’s plat­form in com­bi­na­tion with im­munother­a­pies to take on blad­der can­cer. That’s a goal she’s hop­ing to see play out by 2019.

Chin will join Au­ra’s board of di­rec­tors, along with Lund­beck­fonden Ven­tures’ se­nior part­ner Casper Breum.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may remember that at the beginning of this year, Endpoints News set a goal to go broader and deeper. We are still working towards that, and are excited to share that Beth Snyder Bulik will be joining us on Monday to cover all things pharma marketing. You can sign up for her weekly Endpoints MarketingRx newsletter in your reader profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

During our recent European Biopharma Summit, I talked with Novartis development chief John Tsai about his experiences over the 3-plus years he’s been at the pharma giant. You can read the transcript below or listen to the exchange in the link above.

John Carroll: I followed your career for quite some time. You’ve had more than 20 years in big pharma R&D and you’ve obviously seen quite a lot. I really was curious about what it was like for you three and a half years ago when you took over as R&D chief at Novartis. Obviously a big move, a lot of changes. You went to work for the former R&D chief of Novartis, Vas Narasimhan, who had his own track record there. So what was the biggest adjustment when you went into this position?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a breakthrough.

The Stanford neurologist, a soft-spoken demi-prodigy who became a professor while still a resident, had been obsessed for a decade with how to better define psychiatric disorders. Drugs for depression or bipolar disorder didn’t work for many patients with the conditions, and he suspected the reason was how traditional diagnoses didn’t actually get at the heart of what was going on in a patient’s brain.

Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'

 

Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing expertise in lung cancer. The drug will now take an early lead in the sought-after adjuvant setting — but competitors are on the way.

The FDA on Friday approved Tecentriq as an adjuvant therapy for patients with Stage II-IIIA non small cell lung cancer with PD-(L)1 scores greater than or equal to 1, making it the first drug of its kind approved in an early setting that covers around 40% of all NSCLC patients.

Yao-Chang Xu, Abbisko Therapeutics founder and CEO

Qim­ing-backed Ab­bisko makes $200M+ Hong Kong de­but, as a SPAC and Agenus spin­out al­so price on Nas­daq

Three new entities priced their public debuts late Thursday and early Friday, including a SPAC, a traditional Nasdaq IPO and a Chinese biotech joining the Hong Kong Index.

Shanghai-based Abbisko Therapeutics raised the most money of the triumvirate, garnering $226 million in its Hong Kong debut and pricing at HK$12.46, or roughly $1.60 in US dollars. The blank check company followed up with a $150 million raise, while MiNK Therapeutics priced on Nasdaq at $12 per share and a $40 million raise.

Paul Grayson, Tentarix CEO (Versant)

Phar­ma vet­er­ans re­group with $50M and a plan to dis­cov­er new mul­ti-specifics

While a horde of drugmakers develops bispecific antibodies to more directly target tumor cells — there were about 100 programs in or nearing clinical trials back in May — a new company is emerging to go one step further.

On Thursday, Tentarix Biotherapeutics unveiled a $50 million Series A round to support its next-gen multi-specifics platform. While the field has largely focused on bispecifics, which engage two targets, Tentarix believes its multifunctional programs have the potential to be even more specific, since more conditions must be met for potent activity to occur.

FDA ad­comm votes unan­i­mous­ly in sup­port of a J&J Covid-19 boost­er two months af­ter one-dose shot

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Friday voted 19-0 in favor of authorizing a second shot of J&J’s Covid-19 vaccine to follow at least two months after the initial dose.

Regulators don’t have to follow VRBPAC’s recommendation, but they almost always do. Considering that the CDC’s advisory committee has already been set to review the expanded EUA, VRBPAC’s recommendation is likely to be adopted.